Retatrutide vs Tirzepatide: Comparison Guide

Retatrutide vs Tirzepatide: Comparison Guide

The world of weight management is evolving, with new medications offering hope and effective options for those with obesity. Two names that generate significant discussion are tirzepatide, the active ingredient in Zepbound and Mounjaro, and retatrutide, an investigational medication that, as of October 2026, has completed its main Phase 3 trials but is not yet approved. While both are part of the same class of drugs, they have important differences.

This guide offers a clear, evidence-aware comparison of retatrutide and tirzepatide to help you understand the current landscape and prepare for informed conversations with your healthcare team. Consult your healthcare provider before starting any medication.

Understanding Tirzepatide (Zepbound and Mounjaro)

Tirzepatide is a well-established medication, approved by the U.S. Food and Drug Administration (FDA) and other global regulatory bodies. In the US it is marketed as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. In the UK and India, Mounjaro is the brand used for both type 2 diabetes and weight management.

How Tirzepatide Works

Tirzepatide is a dual-agonist. This means it mimics and activates the receptors for two different naturally occurring hormones in your body:

• GLP-1 (Glucagon-Like Peptide-1): This hormone helps regulate blood sugar, slows down how quickly your stomach empties, and signals a feeling of fullness to your brain.
• GIP (Glucose-Dependent Insulinotropic Polypeptide): This hormone also helps with blood sugar control and is believed to enhance the effects of GLP-1, contributing to appetite suppression and potential weight loss.

By targeting both of these pathways, tirzepatide provides a powerful, multi-faceted approach to improving metabolic health and supporting weight reduction.

Key Findings from Clinical Trials

The approval of tirzepatide for chronic weight management was based on extensive data from the SURMOUNT clinical trial program. In the landmark SURMOUNT-1 study, participants taking the highest dose of tirzepatide, alongside diet and exercise, achieved an average weight loss of 20.9% of their body weight over 72 weeks.

Common side effects are primarily gastrointestinal and include nausea, diarrhea, constipation, and vomiting. These are typically most pronounced when starting the medication or increasing the dose and often lessen over time. Doctors use a gradual dose-escalation schedule to help manage these effects.

Tirzepatide also has important safety warnings. The US label carries a boxed warning about thyroid C-cell tumours in rodents, and tirzepatide should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. It can make oral contraceptive pills less reliable, particularly after starting and after each dose increase, so a non-oral or backup method is advised for a time. Seek urgent help for severe, persistent stomach pain (possible pancreatitis), signs of gallbladder problems, vomiting or diarrhoea that stops you keeping fluids down, or signs of a severe allergic reaction.

Introducing Retatrutide (The "Triple G" Agonist)

Retatrutide is a newer, investigational medication from the same manufacturer as tirzepatide. It is not yet approved for public use. Its main Phase 3 obesity trials have reported, and Lilly has said it plans to submit it to the US FDA in the first quarter of 2027.

How Retatrutide Works

Retatrutide takes the multi-agonist approach a step further. It is a triple-agonist, targeting the GLP-1 and GIP receptors just like tirzepatide, but adding a third:

• Glucagon (GCG) Receptor: Activating the glucagon receptor is thought to contribute to weight loss by increasing energy expenditure (the number of calories your body burns) and further suppressing appetite.

By engaging three distinct hormonal pathways involved in appetite, satiety, and metabolism, retatrutide represents a potential next step in incretin-based therapies.

Trial Results So Far

Retatrutide’s Phase 2 study, published in The New England Journal of Medicine, showed that participants taking the highest dose (12 mg) achieved an average weight loss of 24.2% of their body weight over 48 weeks. In the larger Phase 3 TRIUMPH-1 trial in adults with obesity without diabetes, published in 2026, average weight loss at 80 weeks was 25.0% on 12 mg compared with 3.9% on placebo.

The most common side effects were gastrointestinal, as with tirzepatide and other GLP-1-based medications, and a slow dose-titration plan was used to improve tolerability. Retatrutide trials also reported a dose-related rise in heart rate and dysesthesia (unusual skin sensations such as tingling), which are not typical of tirzepatide.

Head-to-Head Comparison: Key Differences and Similarities

While these two medications are related, their differences are important for understanding the current and future state of weight management treatments.

Mechanism of Action

• Tirzepatide: A dual-agonist that activates GLP-1 and GIP receptors.
• Retatrutide: A triple-agonist that activates GLP-1, GIP, and Glucagon receptors.

Approval Status

• Tirzepatide: Approved and available by prescription for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) in many countries.
• Retatrutide: Investigational. It is not yet approved by the FDA or other regulatory agencies and is only available to participants in clinical trials.

Efficacy in Clinical Trials

• Tirzepatide: Has robust, completed Phase 3 trial data demonstrating significant weight loss (averaging up to 20.9% at 72 weeks). This high-quality evidence led to its official approval.
• Retatrutide: Average weight loss reached 24.2% at 48 weeks in Phase 2 and 25.0% at 80 weeks in the Phase 3 TRIUMPH-1 trial. These trials are not directly comparable with SURMOUNT-1; a head-to-head trial of retatrutide versus tirzepatide (TRIUMPH-5) is ongoing.

Side Effect Profile

Both medications share many side effects that are characteristic of this class of drugs. The most common side effects for both are gastrointestinal, including nausea, diarrhea, and constipation. Retatrutide has also been linked with dysesthesia and a rise in heart rate. Both are administered as a once-weekly injection.

What This Means for Your Health Journey

Understanding these medications is about empowerment. It allows you to have more productive and informed conversations with your healthcare provider about your personal health goals.

The Current Landscape vs. The Future

Today, tirzepatide is an established and effective option available to patients who meet the prescribing criteria. It has a proven track record supported by large-scale clinical trials and real-world use.

Retatrutide, on the other hand, represents the future. It is a clear signal of the direction that research is headed—finding more comprehensive ways to target the complex biology of obesity. While its results are promising, it is not a clinical option for patients today outside a trial. Products sold online as retatrutide are unapproved and their contents are unknown.

Having an Informed Conversation with Your Doctor

This information is designed to be a starting point for a discussion, not a substitute for professional medical advice. When you speak with your doctor, you can use this knowledge to ask thoughtful questions, such as:

• Based on my health profile, what are the approved treatment options for me?
• What are the potential benefits and risks of the available medications?
• How does medication fit into a larger plan that includes nutrition and physical activity?

Your healthcare provider can assess your individual situation, including your health history and treatment goals, to determine the most appropriate path forward. Consult your healthcare provider before starting any medication.

The development of medications like tirzepatide and retatrutide marks a pivotal moment in medicine, offering powerful new tools to support individuals on their path to better health. As science continues to advance, the options for managing chronic weight conditions will only continue to grow.

Sources

• Zepbound (tirzepatide) US prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf
• Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1): https://pubmed.ncbi.nlm.nih.gov/35658024/
• Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
• Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1, NEJM 2026): https://pubmed.ncbi.nlm.nih.gov/42814954/
• A Study of Retatrutide (LY3437943) Compared to Tirzepatide in Adults Who Have Obesity (TRIUMPH-5): https://clinicaltrials.gov/study/NCT06662383
• Eli Lilly Q2 2026 results (SEC Form 8-K, July 2026): https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm